Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel
San Antonio Breast Cancer Symposium
PRESS RELEASES
3-V Biosciences to Present Data at the American Association for the Study of Liver Diseases Annual Meeting 2016 in Boston, MA
Menlo Park, California, November 04, 2016. 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic
Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
International Congress on Targeted Anticancer Therapies
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement
Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement
Keystone Symposium – New Frontiers in Understanding Tumor Metabolism
